Back to top
more

LivaNova (LIVN)

(Real Time Quote from BATS)

$42.54 USD

42.54
336,584

+1.41 (3.43%)

Updated Aug 4, 2025 12:24 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Are Options Traders Betting on a Big Move in LivaNova Stock?

by Zacks Equity Research

Investors need to pay close attention to LivaNova stock based on the movements in the options market lately.

Zacks Equity Research

LivaNova (LIVN) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

LivaNova (LIVN) delivered earnings and revenue surprises of 17.33% and 5.41%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Masimo (MASI) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Masimo (MASI) delivered earnings and revenue surprises of 9.68% and 1.29%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

DexCom (DXCM) Q1 Earnings Miss Estimates

by Zacks Equity Research

DexCom (DXCM) delivered earnings and revenue surprises of -3.03% and 1.99%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

LivaNova (LIVN) Tops Q4 Earnings Estimates

by Zacks Equity Research

LivaNova (LIVN) delivered earnings and revenue surprises of 1.25% and 0.48%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Si-Bone (SIBN) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Si-Bone (SIBN) delivered earnings and revenue surprises of 31.25% and 0.21%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Glaukos (GKOS) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Glaukos (GKOS) delivered earnings and revenue surprises of 6.98% and 4.71%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Moumi Mondal headshot

5 Beaten-Down MedTech Stocks Set to Rebound in 2025

by Moumi Mondal

Investors may want to take a closer look at discounted stocks, such as MCK, HAE, ARAY, LIVN and PBH, in the present market landscape.

Zacks Equity Research

Wall Street Analysts Predict a 37.2% Upside in LivaNova (LIVN): Here's What You Should Know

by Zacks Equity Research

The mean of analysts' price targets for LivaNova (LIVN) points to a 37.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Equity Research

Teladoc Enhances Virtual Sitter With AI for Improved Care Delivery

by Zacks Equity Research

TDOC's upgraded Virtual Sitter uses AI to prevent patient falls, boost staff efficiency and enhance care delivery, thus addressing major challenges in hospitals and health systems.

Zacks Equity Research

LivaNova's OSPREY Sleep Apnea Trail on aura6000 Meets Primary Endpoint

by Zacks Equity Research

LIVN's aura6000 significantly increases responder rates. The device also reduces AHI and ODI levels. A premarket approval application will be filed soon.

Zacks Equity Research

LivaNova (LIVN) Upgraded to Strong Buy: What Does It Mean for the Stock?

by Zacks Equity Research

LivaNova (LIVN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Equity Research

Best Momentum Stocks to Buy for November 7th

by Zacks Equity Research

KRUS, FTDR and LIVN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 7, 2024.

Zacks Equity Research

How Much Upside is Left in LivaNova (LIVN)? Wall Street Analysts Think 38.2%

by Zacks Equity Research

The consensus price target hints at a 38.2% upside potential for LivaNova (LIVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Equity Research

New Strong Buy Stocks for November 7th

by Zacks Equity Research

MCO, EBS, LIVN, FTDR and KRUS have been added to the Zacks Rank #1 (Strong Buy) List on November 7, 2024.

Zacks Equity Research

Best Value Stocks to Buy for November 7th

by Zacks Equity Research

JWN and LIVN made it to the Zacks Rank #1 (Strong Buy) value stocks list on November 7, 2024.

Zacks Equity Research

LivaNova (LIVN) Tops Q3 Earnings and Revenue Estimates

by Zacks Equity Research

LivaNova (LIVN) delivered earnings and revenue surprises of 26.76% and 6.75%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?

by Zacks Equity Research

Sector ETF report for XHE

Zacks Equity Research

LivaNova (LIVN) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

LivaNova (LIVN) delivered earnings and revenue surprises of 17.72% and 4.44%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

LivaNova (LIVN) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

LivaNova (LIVN) delivered earnings and revenue surprises of 62.22% and 6.45%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: Tandem Diabetes Care, Inc. (TNDM) Q1 Earnings Expected to Decline

by Zacks Equity Research

Tandem Diabetes Care (TNDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

LivaNova (LIVN) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

LivaNova (LIVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

LivaNova (LIVN) Soars 12.5%: Is Further Upside Left in the Stock?

by Zacks Equity Research

LivaNova (LIVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

LivaNova (LIVN) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

LivaNova (LIVN) delivered earnings and revenue surprises of 10.13% and 6.94%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

CVRx (CVRX) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

CVRx (CVRX) delivered earnings and revenue surprises of 24.56% and 6.93%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?